Medical therapy in acute coronary syndromes: Which medicines and at what doses?

Current Cardiology Reports

Volumn 11, Issue 4, 2009, Pages 267-275

  Kireyev, Dmitriy ^a   Yun, Edward C ^a   Page, Brian J ^a   Boden, William E ^a  

^a BUFFALO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALTEPLASE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DILTIAZEM; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NITRATE; PLACEBO; PRASUGREL; RETEPLASE; STREPTOKINASE; TENECTEPLASE; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; VERAPAMIL;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ANGINA PECTORIS; ANTICOAGULATION; BLEEDING; BOLUS INJECTION; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FIBRINOLYSIS; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; RECOMMENDED DRUG DOSE; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; ST SEGMENT ELEVATION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSINS; ANTICOAGULANTS; ASPIRIN; ENZYME INHIBITORS; FIBRINOLYTIC AGENTS; HUMANS; NITRATES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS;

EID: 67650337590     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-009-0039-3     Document Type: Review

References (49)

1. Rosamond W, Flegal K, Friday G: Heart disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-e171.
2. Kleinschmidt K, BradA WJ: Acute coronary syndromes: an evidence-based review and outcome-optimizing guidelines for patients with and without procedural coronary intervention (PCI). Part III: Fibrinolytic therapy, procedural coronary intervention, multi-modal approaches, and medical prophylaxis with low molecular weight heparins. In Hospital Medicine Consensus Reports. Atlanta, GA: American Health Consultants; 2001.
3. Nallamothu BK, Bates ER: Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: Is timing (almost) everything? Am J Cardiol 2003, 92:824-826.
4. Van't Hof AW, Ten Berg J, Heestermans T, et al.: Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomized controlled trial. Lancet 2008, 372:509-510.
5. Angeja BG, Alexander JH, Chin R, et al.: Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT trial. Am J Cardiol 2001, 88:1240-1245.
6. Topol EJ, Ohman EM, Armstrong PW, et al.: Survival outcome 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction. Results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO trial). Circulation 2000, 102:1761-1765.
7. Boden WE, Eagle K, Granger CB: Reperfusion strategies in acute ST-segment elevation myocardial infarction: A comprehensive review of contemporary management options. J Am Coll Cardiol 2007, 50:917-929.
8. Wallentin L, Goldstein P, Armstrong PW, et al.: Efficacy and safety of tenecteplase in combination with the lowmolecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003, 108:135-142.
9. Antman EM, Hand M, Armstrong PW, et al.: 2007 Focused Update of the ACC/ AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008, 117:296-329.
10. Antman EM, Morrow DA, McCabe CH, et al.: Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006, 354:1477-1488.
11. Antman EM, Anbe DT, Armstrong PW, et al.: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004, 44:e1-e211.
12. Berger JS, Stebbins A, Granger CB, et al.: Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation 2008, 117:192-199.
13. Anderson JL, Adams CD, Antman EM, et al.: ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2007, 50:652-726.
14. Cannon CP; CAPRIE Investigators: Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 2002, 90:760-762.
15. King S III, Smith S Jr, Hirshfeld J Jr, et al.: 2007 Focused Update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008, 51:172-209.
16. Gurbel PA, Bliden KP, Zaman KA, et al.: Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005, 111:1153-1160.
17. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.: High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004, 25:1903-1910.
18. Chen ZM, Jiang LX, Chen YP, et al.: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomized placebo-controlled trial. Lancet 2005, 366:1607-1621.
19. Sabatine MS, Cannon CP, Gibson CM, et al.; for the CLARITY-TIME 28 Investigators: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352:1179-1189.
20. Wiviott SD, Braunwald E, McCabe CH, et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
21. Montalescot G, Wiviott SD, Braunwald E, et al.: Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-segment elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial. Lancet 2009, 373:723-731.
22. Yusuf S, Zhao F, Mehta SR, et al.; for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
23. Han Y, Li Y, Wang S, et al.: Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study. Am Heart J 2009, 157:733-739.
24. Ferguson JJ, Califf RM, Antman EM, et al.; for the SYNERGY Trial Investigators: Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004, 292:45-54.
25. Yusuf S, Mehta SR, Chrolavicius S, et al.: Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA 2006, 295:1519-1530.
26. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, et al.: Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006, 354:1464-1476.
27. Stone GW, Witzenbichler B, Guagliumi G, et al.; on behalf of the HORIZONS-AMI Trial Investigators: Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358:2218-2230.
28. White H: Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial. Lancet 2001, 358:1855-1863.
29. Stone GW, McLaurin BT, Cox DA, et al.: Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203-2216.
30. Feldman DN, Wong SC, Gade CL, et al.: Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents. Am Heart J 2007, 154:695-701.
31. Pinto DS, Stone GW, Shi C, et al.: Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol 2008, 52:1758-1768.
32. Tcheng JE, Kandzari DE, Grines CL, et al.: Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction. Circulation 2003, 108:1316-1323.
33. Gurm HS, Smith DE, Collins JS, et al.: The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: Insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol 2008, 51:529-535.
34. Zeymer U: The role of eptifibatide in patients undergoing percutaneous coronary intervention. Expert Opin Pharmacother 2007, 8:1147-1154.
35. Topol EJ, Moliterno DJ, Herrmann HC, et al.; for the TARGET Investigators: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001, 344:1888-1894.
36. Valgimigli M, Campo G, Percoco G, et al.: Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction, the MULTISTRATEGY randomized trial. JAMA 2008, 299:1788-1799.
37. Simoons ML; GUSTO IV-ACS Investigators: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: The GUSTO IV-ACS randomized trial. Lancet 2001, 357:1915-1924.
38. Giugliano RP, White JA, Bode C, et al.: Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009 Mar 31 (Epub ahead of print).
39. Chen ZM, Pan HC, Chen YP, et al.: Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: Randomized placebo-controlled trial. Lancet 2005, 366:1622-1632.
40. Jespersen CM: Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials. Cardiovasc Drugs Ther 2000, 14:99-105.
41. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582-1587.
42. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360:752-760.
43. Pfeffer MA, McMurray JJV, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
44. Pitt B, Remme W, Zannad F, et al.; for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
45. Waters D, Schwartz GG, Olsson AG, et al.: The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: A new frontier for statins? Curr Control Trials Cardiovasc Med 2001, 2:111-114.
46. Chaitman BR, Skettino SL, Parker JO, et al.; MARISA Investigators: Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004, 43:1375-1382.
47. Chaitman BR, Pepine CJ, Parker JO, et al.: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 2004, 291:309-316.
48. Stone PH, Gratsiansky NA, Blokhin A, et al.; ERICA Investigators: Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006, 48:566-575.
49. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al.: Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-STElevation Acute Coronary Syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006, 152:400-406.